All In MedTech

Device Trial Radar · NCT03438747

P-15L Bone Graft in Transforaminal Lumbar Interbody Fusion With Instrumentation

An Assessment of P-15L Bone Graft in Transforaminal Lumbar Interbody Fusion With Instrumentation

Last checked: Nov 20, 2026Latest source record: Oct 6, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingRandomized with 290 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

290

Actual

Start

Apr 24, 2018

Primary completion

Feb 28, 2028

Study completion Feb 28, 2028

Sponsor

Lead sponsor
CeraPedics, IncNot on our public-company list
Sponsor type
Industry
First posted
Feb 20, 2018

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Randomized
Model
Parallel
Masking
Double (participant, outcomes assessor)
Primary purpose
Treatment
FDA-regulated device
Yes
Who can join
All sexes, from 22 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The aim of this trial is to evaluate if P-15L bone graft (investigational device) is not inferior in effectiveness and safety to local autologous bone (and allograft where necessary) as an extender (control device) when applied in instrumented transforaminal lumbar interbody fusion (TLIF) in subjects with degenerative disc disease (DDD). In addition to the general overall objective, a sub-group analysis will be performed on the high-risk subject population (tobacco use, obesity, diabetes), as previous studies have shown negative effects of smoking, obesity and diabetes on fusion and bone healing, increased peri/postoperative complications, and lower patient-reported outcome scores.

Conditions

  • Degenerative Disc Disease

Interventions

  • P-15L Bone GraftDevice

    The investigational group will be treated with P-15L in an instrumented TLIF

  • Local autologous bone in a TLIF with InstrumentationOther

    The active control group will be treated local autologous bone in an instrumented TLIF

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Secondary surgical interventionTime frame: 72 Months
  2. FusionTime frame: 72 Months
  3. Oswestry Disability Index (ODI)Time frame: 72 Months

2 more outcomes with a free account

Locations

34 sites in 1 country. Site status is shown where the registry gives one.

  • The University of Alabama at Birmingham

    Birmingham, Alabama

  • Glendale Adventist Medical Center

    Glendale, California

  • Keck School of Medicine USC

    Los Angeles, California

31 more study sites with a free account

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.